Jane Street Group LLC Has $111,000 Stock Holdings in Sera Prognostics, Inc. (NASDAQ:SERA)

Jane Street Group LLC lifted its position in Sera Prognostics, Inc. (NASDAQ:SERA) by 24.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 14,225 shares of the company’s stock after purchasing an additional 2,826 shares during the quarter. Jane Street Group LLC’s holdings in Sera Prognostics were worth $111,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Bank of New York Mellon Corp increased its position in Sera Prognostics by 100.2% in the second quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after purchasing an additional 75,441 shares during the period. Quest Partners LLC raised its position in Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after buying an additional 5,415 shares during the last quarter. State Street Corp grew its position in Sera Prognostics by 8.8% in the third quarter. State Street Corp now owns 425,093 shares of the company’s stock valued at $3,316,000 after purchasing an additional 34,479 shares in the last quarter. American Century Companies Inc. raised its holdings in Sera Prognostics by 12.7% during the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock worth $152,000 after acquiring an additional 2,891 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in Sera Prognostics during the second quarter worth $190,000. Institutional investors own 54.64% of the company’s stock.

Insider Buying and Selling at Sera Prognostics

In other Sera Prognostics news, Director Joshua Phillips sold 12,163 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $6.39, for a total value of $77,721.57. Following the transaction, the director now directly owns 2 shares of the company’s stock, valued at approximately $12.78. The trade was a 99.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Benjamin Jackson sold 13,272 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $7.42, for a total transaction of $98,478.24. Following the transaction, the general counsel now owns 128,473 shares in the company, valued at $953,269.66. This represents a 9.36 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 80,505 shares of company stock worth $572,781 over the last 90 days. Insiders own 15.80% of the company’s stock.

Sera Prognostics Stock Up 0.6 %

Shares of NASDAQ SERA opened at $6.37 on Wednesday. The business’s 50 day moving average price is $7.44 and its two-hundred day moving average price is $7.31. Sera Prognostics, Inc. has a twelve month low of $4.98 and a twelve month high of $12.35. The company has a market cap of $215.13 million, a PE ratio of -6.43 and a beta of 0.86.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.09 million. During the same quarter in the previous year, the company earned ($0.23) earnings per share. As a group, research analysts anticipate that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.